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Objective: The analysis of epidemiology, risk factors and outcome of viral infections in
children and adolescents after hematopoietic cell transplantation (HCT).
Methods: In this multicenter nationwide study a total of 971 HCT procedures (741 allo-
HCT; 230 auto-HCT) over a period of 6 years were analyzed.
Results: During this period 801 episodes of viral infections were diagnosed in 442 patients.
The incidence of viral infections was 57.9% in allo-HCT and 4.8% in auto-HCT patients. The
most frequent infections after allo-HCT were caused by cytomegalovirus (CMV), polyoma
BK virus (BKV) and Epstein–Barr virus (EBV). The majority of infections occurred within
the first 4 months after allo-HCT and over 80% required pharmacotherapy or symptomatic
therapy. The median time of treatment of specific viral infection ranged from 7 (for EBV) to
24 (for CMV) days. The highest mortality was observed in case of CMV infection. The risk
factors for viral infections were allo-HCT, acute leukemia, acute and chronic graft versus
host disease (a/cGVHD), and matched unrelated donor (MUD)/mismatched unrelated donor
(MMUD)-HCT. The risk factor for death from viral infection were CMV-IgG seropositivity
in acute lymphoblastic leukemia recipient, and MUD/MMUD-HCT. The incidence of EBV
infection requiring pre-emptive treatment with rituximab in allo-HCT children was 19.3%. In
30.8% cases of EBV infection, these episodes were preceded by other viral infection and
treated with antivirals, which did not prevent development of EBV-DNA-emia with need of
rituximab treatment in 81.5% cases. In 47.7% of these cases, GVHD was a factor enabling
development of significant EBV-DNA-emia during antiviral therapy of other infection.
Conclusion: We have shown that antiviral drugs do not prevent EBV reactivation in allo-
HCT pediatric patients.
Keywords: children, EBV, HCT, infectious complications, risk factors analysis, viral
infections
Introduction
Infections are the major cause of mobility and mortality in children who are
undergoing hematopoietic cell transplantation (HCT) or chemotherapy due to
malignancy.1–3 According to the Center for International Blood and Marrow
Transplant Research (CIBMTR), infectious complications were the cause of death
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in 7% of autologous HCT (auto-HCT), 11% of matched
sibling donor HCT (MSD-HCT) and 13% of matched
unrelated donor HCT (MUD-HCT) recipients.2 Infectious
complications in children after HCT were noted in 82% of
children after allogeneic HCT (allo-HCT)4 and in 21% of
children with solid tumor or lymphoma in pediatric auto-
HCT setting.5 The incidence of viral infection after allo-
HCT was observed in 19.3% of patients during the first 30
days after transplantation, 18.5% between 31 and 100
days, and in 20% after day +101 up to 2 years after
HCT.4 In the auto-HCT setting viral infections were
observed only in 11% of patients with median onset of
10 days post-transplant.5
Viruses that cause infection after HCTcan be classified as
latent or “episodic” in nature, with the latter acquired typi-
cally after exposure rather than as a result of a reactivation
event.6 In the early post-transplant period herpes simplex
virus (HSV) reactivation was the most frequent viral infec-
tion both in allo-HCT and auto-HCT patients.4,5 Overall, 8%
of allo-HCT patient died primarily due to infections and 24%
of these infections were viral.4 In auto-HCT patients deaths
due to infections were episodic.5
Some major improvements in outcomes were associated
with the application of drugs and molecular tests to detect
and prevent early bacterial infections, HSV, cytomegalo-
virus (CMV), and pre-engraftment candidal infections.6
Screening for reactivation with pre-emptive treatment or
application of prophylaxis in seropositive recipients plays
a role in preventing diseases caused by latent herpesviruses
such as CMV, human herpesvirus 6 (HHV-6), and varicella-
zoster virus (VZV).6 Implementation of diagnostic and
therapeutic strategies for management of Epstein–Barr
virus (EBV) infection, on the basis of monitoring of EBV-
DNA-emia and
pre-emptive or targeted therapy with rituximab, has reduced
the incidence of mortality from post-transplant lymphopro-
liferative disease (EBV-PTLD) from 84% before the year
2000 to 30% in 2013.7 Ganciclovir (GCV) can reduce EBV
replication, but neither ganciclovir/foscarnet (FCV) nor
cidofovir (CDV) therapy/prophylaxis have any impact on
development of EBV-PTLD, so antiviral agents are not
recommended.8
In this multicenter nationwide study we present analy-
sis of the epidemiology, risk factors and outcome of viral
infections in children and adolescents after HCT over
a period of 72 consecutive months. Special attention was
given to antiviral drugs usage and incidence of EBV
infection after HCT.
Materials and Methods
Design of the Study
The study was designed as multicenter nationwide cohort
analysis performed on behalf of the Polish Society of
Pediatric Oncology and Hematology. Viral infections diag-
nosed during a six-year period (between January 1, 2012 and
December 31, 2017), were reported by all Polish pediatric
HCT centers (Bydgoszcz, Krakow, Lublin, Poznan,
Wroclaw) and data were analyzed centrally by two indepen-
dent researchers. Data from the first 2-year period were col-
lected retrospectively, then prospectively afterwards.
Pathogen Diagnosis
Viral infections were classified as episodic (diagnosed on the
basis of clinical manifestation and supplemented with appro-
priate tests) or latent (requiring monitoring at the molecular
level).6,8,9 The following latent viruses were included in the
analysis: CMV, EBV, HHV6, HSV, VZV, polyoma BK virus
(BKV), while episodic viruses included influenza A and
B (FLUAV and FLUBV, respectively) and other community-
acquired respiratory viruses (CARV), such as parainfluenza
(HPIV), human metapneumovirus (hMPV), respiratory syn-
cytial virus (RSV), rhinovirus (RhV), as well as parvovirus
B19 (PVB19), hepatotropic viruses, adenovirus (ADV), rota-
virus (RV), and norovirus (NoV). Detection of RVand NoV in
the stool was performed using a serological method. For all
other viruses polymerase chain reaction (PCR)-based analysis
was used for the diagnosis of viral infections of material
derived from blood, urine, cerebrospinal fluid, respiratory
swabs or bronchoalveolar lavage. According to recommenda-
tions of the European Conference on Infections in Leukaemia
(ECIL), a pre-emptive quantitative approach was introduced
for infections with CMVand EBV in allo-HCT patients.8,9
Recurrent viral infection was defined as a new episode
of viral infection in a patient with previous evidence of the
same viral infection in whom the virus has not been
detected for at least 4 weeks during active surveillance.
Recurrent infection could have resulted from reactivation
of latent virus or exogenous reinfection.10 Multiple viral
infections were defined as infections with two or more
viruses in one patient in any time in the study period.
Significant plasma CMV-DNA-emia and EBV-DNA-emia
were defined with the threshold value ≥1000 copies/mL.
Anti-Infective Management
Standard uniform prophylaxis has been applied for all
patients undergoing HCT.8,9,11 Commonly accepted
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strategies were performed for prophylactic, empirical and
targeted anti-infectious therapy with various agents.8,9,11,12
In the case of significant CMV-DNA-emia and EBV-DNA
-emia and/or CMV- or EBV-disease, specific treatment
was implemented.
Statistical Analysis
An event was defined as the diagnosis of a first specific
infectious disorder. Categorical variables were compared by
the chi-square test, while non-categorical variables were
compared by the Mann–Whitney U test. Hazard ratio (HR)
and confidence intervals (CI) were calculated for the differ-
ence in occurrence of infections in patients. Cumulative
incidences of viral infections were calculated using compet-
ing risk analysis,13 starting from the day of transplantation to
the day of the first specific infection. Death was considered as
the competing event. The Kaplan–Meier method was used to
determine infection-related mortality and overall survival.14
Logistic regression method was used for the multivariate




Over the analysis period of 72 consecutive months, a total of
971 HCT (741 allo-HCT; 230 auto-HCT) were performed.
Indications for HCTs were: acute lymphoblastic leukemia
(ALL, n=233), acute myeloblastic leukemia (AML,
n=151), neuroblastoma (n=138), primary immunodeficien-
cies (n=113), bone marrow failure syndromes (n=101), Non-
Hodgkin Lymphoma and Hodgkin Lymphoma (NHL/HD,
n=65), Ewing sarcoma (n=44), myelodysplastic syndrome
(n=38) and other indications (n=88).
Incidence of Infection
A total of 801 episodes of viral infections were diagnosed
in 442 patients (431 allo-HCT and 11 auto-HCT). Overall,
788 infections (726 primary infections and 62 reinfections)
(Table 1) were diagnosed in allo-HCT, and 13 (11 primary
infections and 2 recurrent infections) in auto-HCT patients
(Supplementary Table 1).
The cumulative incidence of viral infections was
57.9% (95% CI=56.1–59.7) in allo-HCT patients, and
4.8% in auto-HCT patients (95% CI=3.4–6.2) (p<0.001)
(Figure 1A). Due to the small number of infections in the
auto-HCT setting, these data were excluded from further
analysis and are presented in Supplementary Table 1.
In the allo-HCT setting, viral infection with a single
pathogen occurred in 54.0% of patients, while there were
multiple viral infections in 46.0% of patients (29.0% with
two viruses, 13.7% with three viruses, 2.6% with four
viruses and 0.7% with five viruses).
The cumulative incidence of viral infections was
28.9% for CMV, 23.8% for BKV, 22.7% for EBV, 10.7%
for ADV, 5.0% for RV, 1.9% for FLUAV, 1.2% for VZV,
1.2% for HHV-6, 0.7% for RSV, 0.5% NoV, 0.4% for
HPIV, 0.4% for RhV, 0.3% for HSV, 0.1% for hMPV,
0.1% for PVB19 and 0.1% for HBV. The incidence of
CMV, BKV and EBV infections were significantly higher
than ADV (p<0.001) and other viral infections. The cumu-
lative incidence of four most frequent viral infections
is shown in Figure 1B.
Most of the viral infections occurred within the first 4
months from allo-HCT. There were no differences in the
median patient age and median time from allo-HCT to
specific viral infection, with respective values ranging
from 0.4 to 3.8 months. Only in cases of VZV, HSV and
NoV were late infections observed, with a median time 6.5,
7.4 and 7.9 months, respectively (Supplementary Table 2).
Treatment
Of 788 specific viral infections (726 primary infections and
62 recurrent infections) in 631 (80.1%) episodes therapies
were performed: 583 (92.4%) pharmacotherapies and 48
(7.6%) symptomatic therapies. In all episodes of HHV-6,
VZV, HPIV, HSV, hMPV infections, and in 97.6% of CMV,
92.6% FLUAV, 81.7% EBV, 60.0% ADV and 53.0% BKV
infectious episodes specific antiviral pharmacotherapy was
used. No specific pharmacotherapy was used for RV, RhV,
NoV, PVB19 and HBV. The most frequent symptomatic
therapies were used in RV (19/48), ADV (10/48), BKV
(5/48) infections (Table 1). The median time of treatment
of specific viral infection range from 7 days for EBV, RV,
FLUAV, RhV, NoV to 22.5 days for BKV and 24 days for
CMV infections (Supplementary Table 2).
Survival After Infections
There were no deaths related to RV, HHV-6, VZV, RSV, RhV,
NoV, HSV, hMPV, and PVB19 infection. For episodic viral
infections one death was related to FLUAV (survival 92.9%)
and one to HPIV (survival 66.7%). For the four most frequent
viral infections (CMV, BKV, EBV and ADV) survival rate
ranged between 90.3% for ADV infection and 95.4 for EBV
infection and did not differ between specific viral infection
(p=0.3) (Figure 2A). With respect to primary diagnosis,
Dovepress Czyzewski et al





































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1





























EBV* 175 168 7 2 143 Rituximab (n=143) 93.4
Cidofovir (n=2)
ADV* 85 79 6 10 51 Cidofovir (n=48) 90.3
Ganciclovir (n=5)
Foscarnet (n=1)
RV 37 37 0 19 0 – 100.0
FLUAV 14 14 0 1 13 Oseltamivir (n=13) 92.8
HHV-6* 10 9 1 1 10 Foscarnet (n=5) 100.0
Ganciclovir (n=5)
Cidofovir (n=1)
VZV* 9 9 0 0 9 Aciclovir (n=9) 100.0
VZIG (n=1)
RSV* 5 5 0 1 5 IVIG (n=3) 100.0
Ribavirin (n=2)
Ganciclovir (n=2)
RhV 4 3 1 4 0 - 100.0
NoV 4 4 0 4 0 - 100.0
HPIV* 3 3 0 0 3 Ribavirin (n=2) 66.7
Ganciclovir (n=2)
IVIG (n=1)
HSV 2 2 0 0 2 Aciclovir (n=2) 100.0
hMPV 1 1 0 0 1 Ganciclovir (n=1) 100.0
PVB19 1 1 0 1 0 – 100.0
HBV 1 1 0 0 0 – 100.0
Note: *Some of the patients were treated with more than one drug.
Abbreviations: ADV, adenovirus; BKV, BK virus; CMV, cytomegalovirus; CMV-CTL, cytomegalovirus specific T lymphocytes; EBV, Epstein–Barr virus; FLUAV, influenza
A virus; HBV, hepatitis B virus; HHV-6, human herpesvirus 6; hMPV, human metapneumovirus; HPIV, parainfluenza; IVIG, intravenous human immunoglobulins; NoV,
norovirus; PVB19, parvovirus B19; RhV, rhinovirus; RSV, respiratory syncytial virus; RV, rotavirus; VZIG, varicella-zoster human immune globulin; VZV, varicella-zoster virus.
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survival from viral infection was 97.4% (95% CI=95.9–98.9)
in AML and 92.4% (95% CI=90.6–94.2%) in ALL patients
and did not statistically differ between these two (p=0.073)
(Figure 2B) and other primary diseases.
Risk Factor Analysis
Risk Factors for Viral Infections
In multivariate analysis, the risk of infections was higher after
allo-HCT (HR=18.0; p<0.001) than auto-HCT. In allo-HCT
patients, the risk was higher in acute leukemia patients vs other
(HR=1.9; p<0.001), MUD vs MSD (HR=2.6; p<0.001),
MMUD (mismatched unrelated donor) vs MSD (HR=4.2;
p<0.001), acute and chronic graft versus host disease
(a/cGVHD) before infection (HR=1.9; p<0.001 and HR=3.4;
p<0.001, respectively) (Table 2).
Risk Factor for Death from Viral Infection After HCT
Among auto-HCT patients, no child died of viral infection.
For allo-HCT patients, a CMV-IgG positive recipient with
ALL as primary disease was a risk factor for death
(HR=1.5; p=0.045) in multivariate analysis. Other risk
factors for death were MUD vs MSD (HR=2.3; p=0.049)
and MMUD vs MSD (HR=3.8; p<0.001) (Table 3).
Viral Infections Preceding EBV Infection
In order to assess the impact of antivirals on the reactivation
of EBV-DNA-emia, we analyzed the use of all antiviral
drugs within 60 days before the onset of significant EBV-
DNA-emia. Of 175 EBV infectious episodes, in 66 (37.7%)
cases, the infection was preceded by another viral infection,
including CMV (n=21), BKV (n=20), ADV (n=4), RV
Figure 1 (A). The cumulative incidence of viral infections in allo-HCT and auto-HCT patients. (B). The cumulative incidence of four most frequent viral infections in allo-
HCT setting.
Figure 2 (A). Survival from four most frequent viral infections in allo-HCT setting. (B). Survival from viral infections in AML and ALL patients.
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(n=3), FLUAV (n=1), HPIV (n=1), RSV (n=1), VZV (n=1),
or multiple infections (BKV+CMV, n=8; BKV+RV, n=3;
ADV+CMV, n=1; ADV+HHV6, n=1; ADV+RV, n=1)
within 7–56 (median 24) days before the diagnosis of EBV-
DNA-emia. In 54/66 (81.8%) cases, a significant EBV-DNA
-emia has occurred and treatment with rituximab was
required. In 44/54 (81.5%) of these cases viral infections
preceding EBV infection were treated with antiviral drugs,
including: CDV (n=18), GCV (n=17), aciclovir (ACV)
(n=1), oseltamivir (n=1) or drug combinations (FCV+GCV,
n=5; FCV+CDV, n=2; GCV+CDV, n=2). Antivirals were
used for treatment of: CMV (n=16), BKV (n=11), ADV
(n=4), FLUAV (n=1), VZV (n=1) or multiple infections
(BKV+CMV, n=7; BKV+RV, n=1; ADV+CMV, n=1;
ADV+HHV-6, n=1; ADV+RV, n=1). Additionally, in 21/
44 (47.7%) cases, development of significant EBV-DNA-
emia occurred during GVHD (18 acute, 3 chronic). With
respect to antiviral drugs, significant EBV-DNA-emia has
developed in 24/242 (9.9%) GCV therapies, 22/153 (14.4%)
CDV therapies, 9/100 (9.0%) FCV therapies, 1/12 (8.3%)
ACV therapies and 1/13 (7.7%) of oseltamivir therapies.
Discussion
The primary causes of morbidity and non-relapse mortality
following HCTare acute and chronic GVHD, organ dysfunc-
tion and infection.15 Changes in the transplantation
procedure and the implementation of effective supportive
care strategies have decreased the incidence of infectious
complications early after conditioning therapy for allo-
HCT, but have also prolonged the risks beyond day +100.6
These late infections might be caused by all types of micro-
organisms; however, the risks are predictable and surmoun-
table with the use of tailored prevention strategies.6 There are
only a few articles focused on viral complications in children
after HCT.4,5,16,17 Herein we reported the results of multi-
center nationwide study of the epidemiology, risk factors and
outcome of viral infections in children and adolescents after
HCTover a period of six consecutive years. All patients were
treated with the same therapeutic protocols, using compar-
able principles of supportive therapy.
We shown high incidence of viral infections in allo-
HCT patients whereas in auto-HCT patients the incidence
was episodic, comparably with other studies.4,5 This dis-
proportion is a result of allogeneic source of stem cells,
T-cell depletion or CD34 selection, moderate-to-severe
GVHD and use of immunosuppressive drugs (especially
steroids) in allo-HCT patients.11
We observed that CMV had the highest incidence from
all viral infections. CMV is one of the most difficult
Table 2 Multivariate Analysis of Risk Factors for Viral Infection
Risk Factor HR (95%CI) p
Allo- vs auto-HCT 18.0 (13–22) <0.001
allo-HCT
Sex male vs female 0.9 (0.7–1.1) 0.698
Acute leukemia vs other 1.9 (1.4–2.4) <0.001
NHL/HD vs other 1.2 (0.6–1.8) 0.751
Haplo vs other 0.8 (0.2–1.4) 0.825
MUD vs MSD 2.6 (1.6–3.6) <0.001
MMUD vs MSD 4.2 (2.5–5.8) <0.001
BM vs PB 0.9 (0.6–1.2) 0.682
MAC vs RIC 1.3 (0.8–1.9) 0.348
TBI vs chemotherapy 1.2 (0.6–1.8) 0.676
ANC recovery: >D21 vs ≤D21 1.3 (0.7–1.9) 0.513
aGVHD before infection: yes vs no 1.9 (1.2–2.6) <0.001
cGVHD before infection: yes vs no 3.4 (1.9–5.0) <0.001
Note: All statistically significant p-values are given in bold font.
Abbreviations: a/cGVHD, acute/chronic graft versus host disease; ALL, acute
lymphoblastic leukemia; ANC, absolute neutrophil count; BM, bone marrow; D,
days; HCT, hematopoietic cell transplantation; HD, Hodgkin lymphoma; MAC,
myeloablative conditioning; MMUD, mismatched unrelated donor; MUD, matched
unrelated donor; MSD, matched sibling donor; NHL, Non-Hodgkin lymphoma; RIC,
reduced-intensity of conditioning; PB, peripheral blood; TBI, total body irradiation.
Table 3 Multivariate Logistic Regression Analysis for Risk
Factors for Death from Viral Infection After HCT
Risk Factor HR (95%CI) p
CMV-IgG+ in recipient and ALL 1.5 (1.1–2.0) 0.045
Sex male vs female 1.1 (0.8–1.5) 0.829
Acute leukemia vs other 1.5 (0.8–2.4) 0.413
NHL/HD vs other 0.9 (0.4–1.6) 0.918
Haplo vs other 1.2 (0.6–1.9) 0.353
MUD vs MSD 2.3 (1.0–3.8) 0.049
MMUD vs MSD 3.8 (1.5–7.1) <0.001
BM vs PB 0.9 (0.4–1.8) 0.740
MAC vs RIC 1.2 (0.6–1.9) 0.762
TBI vs chemotherapy 1.3 (0.5–2.2) 0.541
aGVHD before infection: yes vs no 1.0 (0.5–1.6) 0.849
cGVHD before infection: yes vs no 1.6 (0.7–2.5) 0.092
ANC recovery: >D21 vs ≤D21 1.0 (0.5–1.5) 0.955
First infection: <D30 vs ≥D30 1.2 (0.6–2.1) 0.834
Treatment duration of infection: >D21
vs ≤D21
1.7 (0.8–2.6) 0.171
Note: All statistically significant p-values are given in bold font.
Abbreviations: a/cGVHD, acute/chronic graft versus host disease; ALL, acute
lymphoblastic leukemia; ANC, absolute neutrophil count; BM, bone marrow;
CMV, cytomegalovirus; D, days; HCT, hematopoietic cell transplantation; HD,
Hodgkin lymphoma; HR, hazard ratio; MAC, myeloablative conditioning; MMUD,
mismatched unrelated donor; MSD, matched sibling donor; MUD, matched unre-
lated donor; NHL, Non-Hodgkin lymphoma; PB, peripheral blood; RIC, reduced-
intensity of conditioning; TBI, total body irradiation.
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infections that occur after allo-HCT.18 The CMV serosta-
tus of the donor and recipient before transplantation sig-
nificantly influence the incidence of CMV recurrence,
whereas the immunosuppressive status of the recipient is
the most important factor for CMV infection.10 Monitoring
by a sensitive technique such as PCR tests of whole blood
allows intervention before development of CMV disease.
Pre-emptive therapy can be used as a standalone strategy
or combined with antiviral prophylaxis. Recently, letermo-
vir, given as prophylaxis, was shown to reduce the risk of
clinically significant CMV infection.18 We have shown
that ganciclovir and foscarnet were the most frequently
used drugs in our cohort for the therapy of CMV reactiva-
tion; accordingly to currently recommended first-line pre-
emptive treatment.18 Nevertheless, management of
patients with resistant or refractory CMV infection or
CMV disease is a challenge. Combination therapy (ganci-
clovir and foscarnet), cidofovir, leflunomide or artesunate
can be considered in patients resistant or refractory to
other second-line and third-line antiviral drugs, and immu-
nosuppression should always be reduced, if possible.18
We observed that cumulative incidence of BKV infec-
tion was 23.8% with survival rate of 90.7%. Cesaro et al.
reported that BKV-related hemorrhagic cystitis occurred in
8–25% of pediatric and 7–54% of adult recipients under-
going allo-HCT.19 Specific anti-BKV prophylaxis is not
available and fluoroquinolones are not recommended
given the lack of significant effects on BKV replication
and hemorrhagic cystitis severity, and the selection of
antibiotic resistance.19 In our study cidofovir was the
most frequently used drug in the treatment of BKV infec-
tion. Cidofovir at a dose of 3–5 mg/kg every 1–2 weeks
with probenecid, or 0.5–1.5 mg/kg 1–3 times/week with-
out probenecid, were used by other authors for the treat-
ment of BKV hemorrhagic cystitis, although without
strong recommendation on its use in these doses.19
The clinical manifestations of ADV infections in immu-
nocompetent hosts include upper respiratory disease, gas-
troenteritis or (kerato-)conjunctivitis and are self-limited in
most cases, although severe manifestations including ence-
phalitis, myocarditis, and pneumonia have been sporadi-
cally observed. In immunocompromised patients, ADV
can cause systemic disease and lethal organ damage.20
Prophylactic antiviral therapy with available antiviral
drugs is currently not recommended and intravenous cido-
fovir is currently regarded as a standard of care in cases of
ADV disease.20 Children are more frequently affected with
ADV than adults (6–28% vs 0–6%, respectively);20 we
observed 10.7% incidence of ADV infection with 90.3%
survival rate.
A relatively low percentage of infections with CARV
origin was observed in our analysis. CARV respiratory
tract infections have been recognized as a significant
cause of morbidity and mortality in patients with leukemia
and those undergoing HCT.12,21 In the late 1990s the
frequency of documented respiratory virus infections was
3.5% among allo-HCT and 0.4% among auto-HCT.22
However, in that time period, viral antigen detection by
immunofluorescence or enzyme immunoassays were used
in diagnostics.22 During the last decade, rapid and highly
sensitive molecular tests have been developed and made
available, with the most recent multiplex PCR platform
that can detect multiple viral pathogens.21 Choi et al.
reported in allo-HCT children the incidence 28.1% of
RhV infection, 25.8% RSV, 18% HPIV, 1.1% hMPV; yet
more than half of the infections were acquired during
hospitalization.17 In the case of CARV infections, ribavirin
and intravenous immunoglobulin are recommended in
hMPV, HPIV and RSV infections, while there is insuffi-
cient evidence for the specific recommendation against
infections caused by coronavirus and RhV.12
We observed a relatively low (1.2%) rate of influenza
A infection, with no cases of influenza B infection, which
may be due to environmental prophylaxis (annual vaccina-
tion of patients, household contacts, and hospital and pro-
phylactic use of neuraminidase inhibitors during influenza
season in some cases). The current guidelines of the 4th
European Conference of Infections in Leukemia (ECIL-4)
recommend diagnosis based on PCR of material collected
from the respiratory tract, especially broncho-alveolar
lavage.23 Neuraminidase inhibitors (oral oseltamivir or
inhalation of zanamivir) are currently the most effective
therapeutic agents for influenza.23
RV and NoV are important pathogens of viral gastro-
enteritis in children. We observed that cumulative inci-
dence of RV was 5% while NoV was 0.5%, treated only
with symptomatic therapy and no deaths were observed. In
other studies the incidence of RV infection varied from
2.3% in adult allo-HCT and auto-HCT recipients up to
19.6% in pediatric allo-HCT recipients.24,25 In pediatric
HCT, the incidence of NoV-associated gastroenteritis was
reported in 12.9% with no NoV-related mortality.26 PCR
as well virus antigen detection in stool are commonly used
in diagnosis of RV and NoV infection. No specific prophy-
laxis against RV- and NoV-related gastroenterocolitis is
Dovepress Czyzewski et al
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available; however, oral immunoglobulins and nitazoxa-
nide were used in some studies.24,27
In immunocompetent individuals primary EBV infection
or reactivation induces usually asymptomatic infection or
infectious mononucleosis.28 In immunocompromised patients
most EBV reactivations are subclinical and require no
therapy.8 However, it may be manifested as encephalitis/mye-
litis, pneumonia, hepatitis and EBV-associated tumors as
PTLD.8,29 After transplantation 14–65% of recipients devel-
oped EBV reactivation,28 while the incidence of EBV-PTLD
varies from 0.45% to 29%, according to the source of hema-
topoietic cells, the associated cell manipulation, and the details
of immunosuppressive regimens used.30 We observed high
incidence of EBV infection (22.7%) in allo-HCT patients,
while there were no cases in auto-HCT setting. In 80.3%
(143/175) of EBV reactivations rituximab was used and
93.3% of patients survived this infection. We also observed
that in almost 1/3 of EBV reactivations, these episodes were
preceded by other viral infection treated with antivirals, which
did not prevent the development of significant EBV-DNA-
emia with the need of rituximab treatment. This is clinically
proven evidence that antiviral drugs do not prevent EBV
reactivation in allo-HCT pediatric patients. Antiviral agents,
such as ganciclovir, are not active against EBV, presumably
because of low levels of viral thymidine kinase expression
during lytic phase, and a lack of expression during latency.8
Intravenous immunoglobulins also have no impact in PTLD.
Neither ganciclovir/foscarnet nor cidofovir therapy/prophy-
laxis have any impact on the development of EBV-PTLD, so
antiviral agents are not recommended.8 Prospective monitor-
ing of EBV-DNA-emia is recommended in patients after allo-
HCT, and these patients should be closely monitored for
symptoms and/or signs attributable to EBV infection and
PTLD.8 The following pre-emptive therapies are recom-
mended after high-risk allo-HCT: rituximab (375 mg/m2/
weekly), reduction of immunosuppressive therapy (if possi-
ble), donor EBV-specific cytotoxic T-cells (EBV-CTL) infu-
sion (if available).8 Compared with rituximab, adoptive
cellular immunotherapy has higher response rate (50–88%)
and fewer relapse.28
We found that allo-HCT, acute leukemia, a/cGVHD,
MUD/MMUD-HCT were the risk factors for viral infec-
tions. CMV donor/recipient serostatus, era of transplanta-
tion, MUD-HCT, and cGVHD were found in other studies
as risk factors for viral infection.4 We have also found that
CMV-IgG seropositivity in ALL recipients, and MUD/
MMUD-HCT were the risk factors for deaths from viral
infection in children after HCT. This is a unique observa-
tion, as there is no study available analyzing this issue.
Conclusions
The incidence of viral infectionswas high in allo-HCTpatients
while in auto-HCT patients viral infections were episodic. The
most frequent viral infection after allo-HCTwere CMV, BKV
and EBV. Most viral infections occurred within the first 4
months after allo-HCT and over 80% required pharmacother-
apy or symptomatic therapy. The median time of treatment of
specific viral infection ranged from 7 (for EBV) to 24 days (for
CMV). The highest infection-relatedmortalitywas observed in
case of CMV infection, whereas primary diagnosis did not
influence survival from viral infection. The risk factors for
viral infections were allo-HCT, acute leukemia, a/cGVHD,
MUD/MMUD vs MSD. The risk factor for death from viral
infectionwere CMV-IgG seropositivity in acute lymphoblastic
leukemia recipients, MUD/MMUDvsMSD. The incidence of
EBV infection requiring pre-emptive treatment with rituximab
in allo-HSCT children was 19.3%. In 30.8% of cases of EBV
infection, these episodeswere preceded by other viral infection
treated with antivirals, which did not prevent development of
significant EBV-DNA-emia with the need of rituximab treat-
ment in 81.5% of cases. This is clinically proven evidence that
antiviral drugs do not prevent EBV reactivation in allo-HCT
pediatric patients.Additionally, in 47.7%of these casesGVHD
was a risk factor, possibly facilitating development of signifi-
cant EBV-DNA-emia during antiviral therapy of other
infections.
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Infections in Leukaemia; FCV, foscarnet; FLUAV, influenza
A virus; FLUBV, influenza B virus; GCV, ganciclovir; HBV,
hepatitis B virus; HCT, hematopoietic cell transplantation; HD,
Hodgkin lymphoma; HHV-6, human herpesvirus 6; hMPV,
human metapneumovirus; HPIV, parainfluenza; HR, hazard
ratio; HSV, herpes simplex virus; IQR, quartiles; MAC, mye-
loablative conditioning; MEL, melphalan; MMUD, mis-
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